NO20013220D0 - Trombineinhibitorer - Google Patents

Trombineinhibitorer

Info

Publication number
NO20013220D0
NO20013220D0 NO20013220A NO20013220A NO20013220D0 NO 20013220 D0 NO20013220 D0 NO 20013220D0 NO 20013220 A NO20013220 A NO 20013220A NO 20013220 A NO20013220 A NO 20013220A NO 20013220 D0 NO20013220 D0 NO 20013220D0
Authority
NO
Norway
Prior art keywords
formula
trombineinhibitorer
anticoagulants
class
compounds
Prior art date
Application number
NO20013220A
Other languages
English (en)
Other versions
NO321739B1 (no
NO20013220L (no
Inventor
Koo Lee
Won Hyuk Jung
Cheol Won Park
Sang Koo Lee
Sun Hwa Lee
Hee Dong Park
Original Assignee
Lg Ci Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Ci Ltd filed Critical Lg Ci Ltd
Publication of NO20013220D0 publication Critical patent/NO20013220D0/no
Publication of NO20013220L publication Critical patent/NO20013220L/no
Publication of NO321739B1 publication Critical patent/NO321739B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
NO20013220A 1998-12-29 2001-06-27 Nye forbindelser som er trombin-inhibitorer NO321739B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19980060266 1998-12-29
KR1019990033490A KR20000047461A (ko) 1998-12-29 1999-08-14 트롬빈 억제제
PCT/KR1999/000830 WO2000039124A1 (en) 1998-12-29 1999-12-29 Thrombin inhibitors

Publications (3)

Publication Number Publication Date
NO20013220D0 true NO20013220D0 (no) 2001-06-27
NO20013220L NO20013220L (no) 2001-08-27
NO321739B1 NO321739B1 (no) 2006-06-26

Family

ID=26634497

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013220A NO321739B1 (no) 1998-12-29 2001-06-27 Nye forbindelser som er trombin-inhibitorer

Country Status (22)

Country Link
US (2) US6492402B1 (no)
EP (1) EP1140918B1 (no)
JP (1) JP3847092B2 (no)
KR (2) KR20000047461A (no)
CN (1) CN1149210C (no)
AT (1) ATE273305T1 (no)
AU (1) AU765417B2 (no)
BR (1) BR9916678A (no)
CA (1) CA2355281A1 (no)
CZ (1) CZ20012429A3 (no)
DE (1) DE69919397T2 (no)
DK (1) DK1140918T3 (no)
ES (1) ES2226482T3 (no)
HK (1) HK1044936A1 (no)
HU (1) HUP0104500A3 (no)
IL (1) IL143545A (no)
NO (1) NO321739B1 (no)
NZ (1) NZ513174A (no)
RU (1) RU2221808C2 (no)
TR (1) TR200101899T2 (no)
WO (1) WO2000039124A1 (no)
ZA (1) ZA200104780B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061609A2 (de) * 1999-04-09 2000-10-19 Basf Aktiengesellschaft Prodrugs von thrombininhibitoren
DE19933861A1 (de) * 1999-07-23 2001-01-25 Basf Ag Verfahren zur Herstellung von 2-Aminomethyl-4-cyano-thiazol
DE19934066A1 (de) * 1999-07-23 2001-01-25 Basf Ag Verfahren zur Herstellung von 4-Cyano-2-aminomethylthiazol
DE10049937A1 (de) * 2000-10-06 2002-04-11 Knoll Ag Niedermolekulare Inhibitoren von Serinproteasen mit Polyhydroxyalkyl- und Polyhydroxycycloalkylresten
KR100447421B1 (ko) * 2001-04-04 2004-09-07 주식회사 엘지생명과학 5-(아미노메틸)-2-티오펜카보니트릴 염산염의 연속반응에의한 새로운 제조방법
RU2004131204A (ru) * 2002-03-22 2005-04-10 Эл Джи Лайф Сайенсиз Лтд. (Kr) НОВЫЕ КРИСТАЛЛИЧЕСКИЕ ФОРМЫ (2S)-N-5-[АМИНО(ИМИНО)МЕТИЛ]-2-ТИЕНИЛМЕТИЛ-1-(2R)- [(КАРБОКСИМЕТИЛ)АМИНО]-3 ,3-Д ИФЕНИЛПРОПАНОИЛ-2-ПИРРОЛИДИНКАРБОКСАМИДА·nH2O
IL164045A0 (en) * 2002-03-22 2005-12-18 Lg Life Sciences Ltd Maleic acid salt of (2S)-N-ä5-Äamino(imino)methylÜ--2-thienylümethyl-1-ä(2R)-2Ä(carboxamide)aminoÜ-3,3-diphenylpr
AU2003245060A1 (en) * 2002-06-27 2004-01-19 Lg Life Sciences Ltd. Peptidic thrombin inhibitor compound
US7097967B2 (en) 2002-10-24 2006-08-29 Lg Life Sciences Ltd. Method of predicting drug-food interaction
US7399870B2 (en) * 2004-03-30 2008-07-15 Wyeth Synthesis of pyrrole-2-carbonitriles
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US7678917B2 (en) * 2005-09-01 2010-03-16 Hoffman-La Roche Inc. Factor Xa inhibitors
JP5129143B2 (ja) 2005-10-07 2013-01-23 エグゼリクシス， インコーポレイテッド Ｍｅｋインヒビターおよびその使用方法
WO2007137080A2 (en) 2006-05-23 2007-11-29 Irm Llc Compounds and compositions as channel activating protease inhibitors
US20080287687A1 (en) * 2006-11-03 2008-11-20 Ajinomoto Co. Inc Production method of diphenylalanine-Ni (II) complex
CA2677487A1 (en) 2007-02-09 2008-08-14 Irm Llc Compounds and compositions as channel activating protease inhibitors
WO2008135525A2 (en) * 2007-05-02 2008-11-13 Boehringer Ingelheim International Gmbh Substituted azetidines, manufacturing and use thereof as medicaments
CA2829790C (en) 2010-03-30 2018-06-05 Verseon Corporation Multisubstituted aromatic compounds as inhibitors of thrombin
US9273028B2 (en) 2010-10-29 2016-03-01 Biogen Ma Inc. Heterocyclic tyrosine kinase inhibitors
SI2909188T1 (en) 2012-10-12 2018-07-31 Exelixis, Inc. A novel process for the manufacture of compounds for use in the treatment of cancer
AU2014238478B2 (en) 2013-03-15 2018-07-19 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
MX2015012867A (es) 2013-03-15 2016-06-10 Verseon Corp Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
WO2016044662A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
SG10201907699YA (en) 2015-02-27 2019-09-27 Verseon Corp Substituted pyrazole compounds as serine protease inhibitors
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3985002A1 (en) 2017-03-01 2022-04-20 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
SG11202010925UA (en) * 2018-05-29 2020-12-30 Omeros Corp Masp-2 inhibitors and methods of use
EP3847174A4 (en) 2018-09-06 2022-06-15 Achillion Pharmaceuticals, Inc. MORPHIC FORMS OF COMPLEMENT D FACTOR INHIBITORS
MX2021003425A (es) 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
BR112021018456A2 (pt) * 2019-03-22 2021-11-23 Achillion Pharmaceuticals Inc Compostos farmacêuticos para o tratamento de distúrbios mediados por complemento
IL293550A (en) 2019-12-04 2022-08-01 Omeros Corp 2-masp inhibitor compounds, preparations containing them and their uses
WO2023183405A2 (en) * 2022-03-22 2023-09-28 Alexion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement mediated disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
ZA951617B (en) * 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5932567A (en) 1995-02-10 1999-08-03 Basf Aktiengesellschaft Thrombin inhibitors
US5914319A (en) 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
IL123986A (en) * 1997-04-24 2011-10-31 Organon Nv Medicinal compounds
AU751111B2 (en) * 1998-01-26 2002-08-08 Basf Aktiengesellschaft Thrombin inhibitors
AU2424499A (en) * 1998-01-26 1999-08-09 Basf Aktiengesellschaft Heterocyclic amidines as callicrein protease inhibitors

Also Published As

Publication number Publication date
ATE273305T1 (de) 2004-08-15
AU1895100A (en) 2000-07-31
US20030134801A1 (en) 2003-07-17
ES2226482T3 (es) 2005-03-16
JP2002533460A (ja) 2002-10-08
HUP0104500A2 (hu) 2002-04-29
HK1044936A1 (zh) 2002-11-08
TR200101899T2 (tr) 2001-12-21
CN1332737A (zh) 2002-01-23
HUP0104500A3 (en) 2002-06-28
CA2355281A1 (en) 2000-07-06
CN1149210C (zh) 2004-05-12
KR20000047461A (ko) 2000-07-25
KR20010086468A (ko) 2001-09-12
CZ20012429A3 (cs) 2001-10-17
EP1140918B1 (en) 2004-08-11
DE69919397D1 (de) 2004-09-16
RU2221808C2 (ru) 2004-01-20
US6492402B1 (en) 2002-12-10
EP1140918A1 (en) 2001-10-10
AU765417B2 (en) 2003-09-18
US6864249B2 (en) 2005-03-08
ZA200104780B (en) 2003-06-12
JP3847092B2 (ja) 2006-11-15
IL143545A0 (en) 2002-04-21
DK1140918T3 (da) 2004-12-20
NZ513174A (en) 2003-10-31
NO321739B1 (no) 2006-06-26
NO20013220L (no) 2001-08-27
KR100462974B1 (ko) 2004-12-23
BR9916678A (pt) 2001-10-16
DE69919397T2 (de) 2005-07-28
IL143545A (en) 2005-08-31
WO2000039124A1 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
ATE273305T1 (de) Thrombin-inhibitoren
ATE297203T1 (de) Antithrombotische mitteln
CY1107634T1 (el) Φαρμακευτικη συνθεση
ATE306261T1 (de) Antithrombosemittel
EA199900937A1 (ru) Фармацевтические композиции, содержащие вориконазол
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
ATE272633T1 (de) Aromatische amiden
NO20003018L (no) Triazinangiogenese-inhibitorer
DK0705254T3 (da) Phenylheterocykliske forbindelser som cyclooxygenase-2-inhibitorer
SE9203825D0 (sv) Dual inhibitors of no synthase and cyclooxygenase, process for their preparation and therapeutical compositions containing them
EE200200045A (et) Asendatud oksoasaheterotsüklüülühendid, farmatseutiline kompositsioon ja vaheühendid
TR200002182T2 (tr) İkame edilmiş aksozaherosayklil faktör xa inhibitörleri
DE69931393D1 (de) Antithrombotische amide
NO991494L (no) <beta>-sulfonylhydroksaminsyrer som matriksmetalloproteinaseinhibitorer
EA200500312A1 (ru) Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз
DK0715623T3 (da) Blodpladeaggregationsinhibitorer
UY26780A1 (es) Cicloalquil avb3 antagonistas
CO5261493A1 (es) Procedimiento y compuestos para la inhibicion de la mrp1
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
DK0804418T3 (da) Platelataggregationshæmmere
ATE308540T1 (de) Antithrombosemittel
ATE253359T1 (de) Antithrombotische mittel
NO20022977L (no) Substituerte homopiperidinylbenzimidazolanaloger som fundiske relaksanter
ATE382607T1 (de) Antitrombotische aether